Success Metrics

Clinical Success Rate
89.8%

Based on 230 completed trials

Completion Rate
90%(230/256)
Active Trials
9(3%)
Results Posted
40%(92 trials)
Terminated
26(8%)

Phase Distribution

Ph early_phase_1
11
3%
Ph not_applicable
40
12%
Ph phase_2
63
20%
Ph phase_1
74
23%
Ph phase_3
70
22%
Ph phase_4
63
20%

Phase Distribution

85

Early Stage

63

Mid Stage

133

Late Stage

Phase Distribution321 total trials
Early Phase 1First-in-human
11(3.4%)
Phase 1Safety & dosage
74(23.1%)
Phase 2Efficacy & side effects
63(19.6%)
Phase 3Large-scale testing
70(21.8%)
Phase 4Post-market surveillance
63(19.6%)
N/ANon-phased studies
40(12.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

84.6%

230 of 272 finished

Non-Completion Rate

15.4%

42 ended early

Currently Active

9

trials recruiting

Total Trials

323

all time

Status Distribution
Active(11)
Completed(230)
Terminated(42)
Other(40)

Detailed Status

Completed230
unknown40
Terminated26
Withdrawn16
Recruiting6
Active, not recruiting3

Development Timeline

Analytics

Development Status

Total Trials
323
Active
9
Success Rate
89.8%
Most Advanced
Phase 4

Trials by Phase

Early Phase 111 (3.4%)
Phase 174 (23.1%)
Phase 263 (19.6%)
Phase 370 (21.8%)
Phase 463 (19.6%)
N/A40 (12.5%)

Trials by Status

not_yet_recruiting21%
active_not_recruiting31%
terminated268%
withdrawn165%
recruiting62%
completed23071%
unknown4012%

Recent Activity

Clinical Trials (323)

Showing 20 of 323 trialsScroll for more
NCT07102979Not Applicable

Remedial Mechanism of Simvastatin and Ursodeoxycholic Acid in Liver Cirrhosis: Crosstalk of Bile Secretion, Gut Microbiome, and Host Immune Response

Terminated
NCT02968810Phase 2

Simvastatin in Preventing Liver Cancer in Patients With Liver Cirrhosis

Active Not Recruiting
NCT05464810Early Phase 1

Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer

Recruiting
NCT07625930Phase 2

RESTAGE (REpurposing STAtins to Improve Outcomes in GastroEsophageal Cancer) Trial

Not Yet Recruiting
NCT03929744Phase 1

A Study of LY3502970 in Healthy Participants

Completed
NCT07692620Not Applicable

Alveolar Ridge Splitting With Simvastatin/PRF Composite and Simultaneous Implant Placement

Completed
NCT06186622Phase 1

A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese Participants

Completed
NCT05771675Early Phase 1

Simvastatin Treatment to Improve Patient-reported Outcomes in Patients With Chronic Pancreatitis

Recruiting
NCT04514029Early Phase 1

Neurotoxicity Prophylaxis With Intrathecal Dexamethasone and Simvastatin Post Axi-Cel

Active Not Recruiting
NCT00858637Phase 3

Efficacy and Safety Study of MCI-196 Versus Simvastatin for Dyslipidaemia in Chronic Kidney Disease (CKD) Subjects on Dialysis

Completed
NCT02675309Phase 1

A Study to Investigate the Effect of MT-8554 on the Pharmacokinetics of Simvastatin and Rosuvastatin in Healthy Subjects

Completed
NCT02197234Phase 1

Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLC

Completed
NCT03889795Phase 1

Phase IB Metformin, Digoxin, Simvastatin in Solid Tumors

Active Not Recruiting
NCT06948747Phase 1

A Study to Investigate the Effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the Effect of Erythromycin on AZD5004 in Healthy Participants

Completed
NCT06858332

Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia

Recruiting
NCT03896217Phase 2

Simvastatin in Secondary Progressive Multiple Sclerosis

Completed
NCT07031778Early Phase 1

Topic Simvastatin for Bone Regeneration

Recruiting
NCT01602029Phase 2

Randomized Double Blind Placebo Control Study in Patients with Schizophrenia

Completed
NCT03387670Phase 3

Multiple Sclerosis-Simvastatin Trial 2

Completed
NCT00166530Phase 4

EASEGO Study: Doubling of Atorvastatin/Simvastatin or INEGY in Patients With Hypercholesterolemia and Coronary Artery Disease(CAD)(0653A-089)

Completed

Drug Details

Intervention Type
DRUG
Total Trials
323